<DOC>
	<DOCNO>NCT01527630</DOCNO>
	<brief_summary>This trial conduct Japan . The aim trial investigate bioequivalence two formulation biphasic insulin aspart 50 ( NN-X14Mix50 ) healthy Japanese subject .</brief_summary>
	<brief_title>Bioequivalence Two Formulations Biphasic Insulin Aspart 50 Healthy Japanese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Considered generally healthy upon completion medical history physical examination , judge Investigator SubInvestigator . Body Mass Index ( BMI ) 1929 kg/m^2 ( inclusive ) Fasting plasma glucose 3.86.0 mmol/L ( inclusive ) Clinically significant abnormal haematology , biochemistry urinalysis screening test , judge Investigator SubInvestigator Any serious systemic infectious disease occur 4 week prior screen , judge Investigator SubInvestigator Any intercurrent illness might affect blood glucose , judge Investigator SubInvestigator Hepatitis B C , HIV ( human immunodeficiency virus ) positive Subjects first degree relative diabetes mellitus History presence diabetes , cancer clinically significant cardiac , respiratory , metabolic , renal , hepatic , gastrointestinal , endocrinological , dermatological , venereal , haematologic , neurologic , psychiatric disease disorder Subjects consume 28 unit alcohol per week significant history alcoholism drug/chemical abuse Subjects smoke 5 cigarette per day Subjects take part strenuous exercise within 7 day prior screen</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>